Literature DB >> 24966258

Schnitzler's syndrome: a diagnostic conundrum.

Catherine Fairris1, Amrit Darvay1.   

Abstract

A 63-year-old man was referred to the rheumatology unit with myalgia, arthralgia and a widespread rash. He was investigated for rheumatological disease; however, this did not yield any specific findings. His symptoms were attributed to statin use and newly started antihypertensives which were promptly discontinued. There was some subsequent improvement in his symptoms so he was discharged. He re-presented 3 years later with pelvic bone pain which had responded to a course of oral steroids started by the general practitioner, who was treating a presumed diagnosis of polymyalgia rheumatica. However, MRI of the pelvis showed bone marrow oedema and the diagnosis was changed to mastocytosis. He did not tolerate or respond to initial treatment. It was not until a second opinion was sought from the dermatologists that the diagnosis of Schnitzler's syndrome was made and treatment with anakinra (an interleukin-1 receptor antagonist) was started with almost complete resolution of his symptoms. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24966258      PMCID: PMC4078520          DOI: 10.1136/bcr-2013-202210

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.

Authors:  Roy M Fleischmann; Joy Schechtman; Ralph Bennett; Malcolm L Handel; Gerd-Rudiger Burmester; John Tesser; Dennis Modafferi; Jennifer Poulakos; Gordon Sun
Journal:  Arthritis Rheum       Date:  2003-04

Review 2.  The Schnitzler syndrome. Four new cases and review of the literature.

Authors:  D Lipsker; Y Veran; F Grunenberger; B Cribier; E Heid; E Grosshans
Journal:  Medicine (Baltimore)       Date:  2001-01       Impact factor: 1.889

3.  Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.

Authors:  H D de Koning; E J Bodar; A Simon; J C H van der Hilst; M G Netea; J W M van der Meer
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

Review 4.  The Schnitzler syndrome.

Authors:  Dan Lipsker
Journal:  Orphanet J Rare Dis       Date:  2010-12-08       Impact factor: 4.123

  4 in total
  1 in total

Review 1.  Schnitzler's syndrome: lessons from 281 cases.

Authors:  Heleen D de Koning
Journal:  Clin Transl Allergy       Date:  2014-12-05       Impact factor: 5.871

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.